Literature DB >> 18329005

Structure-activity relationship for adenosine kinase from Mycobacterium tuberculosis II. Modifications to the ribofuranosyl moiety.

Mary C Long1, Sue C Shaddix, Omar Moukha-Chafiq, Joseph A Maddry, Lisa Nagy, William B Parker.   

Abstract

Adenosine kinase (Ado kinase) from Mycobacterium tuberculosis is structurally and biochemically unique from other known Ado kinases. This purine salvage enzyme catalyzes the first step in the conversion of the adenosine analog, 2-methyl-Ado (methyl-Ado), into a metabolite with antitubercular activity. Methyl-Ado has provided proof of concept that the purine salvage pathway from M. tuberculosis may be utilized for the development of antitubercular compounds with novel mechanisms of action. In order to utilize this enzyme, it is necessary to understand the topography of the active site to rationally design compounds that are more potent and selective substrates for Ado kinase. A previous structure-activity relationship identified modifications to the base moiety of adenosine (Ado) that result in substrate and inhibitor activity. In an extension of that work, 62 Ado analogs with modifications to the ribofuranosyl moiety, modifications to the base and ribofuranosyl moiety, or modifications to the glycosidic bond position have been analyzed as substrates and inhibitors of M. tuberculosis Ado kinase. A subset of these compounds was further analyzed in human Ado kinase for the sake of comparison. Although no modifications to the ribose moiety resulted in compounds as active as Ado, the best substrates identified were carbocyclic-Ado, 8-aza-carbocyclic-Ado, and 9-[alpha-l-lyxofuranosyl]-adenine with 38%, 4.3%, and 3.8% of the activity of Ado, respectively. The most potent inhibitor identified, 5'-amino-5'-deoxy-Ado, had a K(i)=0.8muM and a competitive mode of inhibition. MIC studies demonstrated that poor substrates could still have potent antitubercular activity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18329005      PMCID: PMC2373907          DOI: 10.1016/j.bcp.2008.01.007

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  46 in total

1.  Adenosine kinase from Cryptosporidium parvum.

Authors:  Jon Galazka; Boris Striepen; Buddy Ullman
Journal:  Mol Biochem Parasitol       Date:  2006-06-27       Impact factor: 1.759

2.  Structural requirements for activity of nucleosides as substrates for adenosine kinase: orientation of substituents on the pentofuranosyl ring.

Authors:  L L Bennett; D L Hill
Journal:  Mol Pharmacol       Date:  1975-11       Impact factor: 4.436

3.  High resolution crystal structures of Mycobacterium tuberculosis adenosine kinase: insights into the mechanism and specificity of this novel prokaryotic enzyme.

Authors:  Manchi C M Reddy; Satheesh K Palaninathan; Nishant D Shetty; Joshua L Owen; Misty D Watson; James C Sacchettini
Journal:  J Biol Chem       Date:  2007-06-26       Impact factor: 5.157

4.  Transgenic overexpression of adenosine kinase aggravates cell death in ischemia.

Authors:  Giuseppe Pignataro; Roger P Simon; Detlev Boison
Journal:  J Cereb Blood Flow Metab       Date:  2006-05-10       Impact factor: 6.200

5.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.

Authors:  Y Cheng; W H Prusoff
Journal:  Biochem Pharmacol       Date:  1973-12-01       Impact factor: 5.858

6.  Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial.

Authors:  Beatriz Grinsztejn; Bach-Yen Nguyen; Christine Katlama; Jose M Gatell; Adriano Lazzarin; Daniel Vittecoq; Charles J Gonzalez; Joshua Chen; Charlotte M Harvey; Robin D Isaacs
Journal:  Lancet       Date:  2007-04-14       Impact factor: 79.321

7.  Synthesis, biological evaluation and molecular modeling studies of N6-benzyladenosine analogues as potential anti-toxoplasma agents.

Authors:  Young Ah Kim; Ashoke Sharon; Chung K Chu; Reem H Rais; Omar N Al Safarjalani; Fardos N M Naguib; Mahmoud H el Kouni
Journal:  Biochem Pharmacol       Date:  2007-01-21       Impact factor: 5.858

8.  Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals.

Authors:  Martin Markowitz; Javier O Morales-Ramirez; Bach-Yen Nguyen; Colin M Kovacs; Roy T Steigbigel; David A Cooper; Ralph Liporace; Robert Schwartz; Robin Isaacs; Lucinda R Gilde; Larissa Wenning; Jing Zhao; Hedy Teppler
Journal:  J Acquir Immune Defic Syndr       Date:  2006-12-15       Impact factor: 3.731

9.  The influence of inorganic phosphate on the activity of adenosine kinase.

Authors:  M Maj; B Singh; R S Gupta
Journal:  Biochim Biophys Acta       Date:  2000-01-03

10.  Evaluation of 3-deaza-adenosine analogues as ligands for adenosine kinase and inhibitors of Mycobacterium tuberculosis growth.

Authors:  Mary C Long; Paula W Allan; Mei-Zhen Luo; Mao-Chin Liu; Alan C Sartorelli; William B Parker
Journal:  J Antimicrob Chemother       Date:  2006-11-03       Impact factor: 5.790

View more
  7 in total

1.  Adenosine dysfunction and adenosine kinase in epileptogenesis.

Authors:  Detlev Boison
Journal:  Open Neurosci J       Date:  2010-01-01

2.  South (S)- and North (N)-Methanocarba-7-Deazaadenosine Analogues as Inhibitors of Human Adenosine Kinase.

Authors:  Kiran S Toti; Danielle Osborne; Antonella Ciancetta; Detlev Boison; Kenneth A Jacobson
Journal:  J Med Chem       Date:  2016-07-13       Impact factor: 7.446

Review 3.  Adenosine kinase: exploitation for therapeutic gain.

Authors:  Detlev Boison
Journal:  Pharmacol Rev       Date:  2013-04-16       Impact factor: 25.468

4.  DNA replication fidelity in Mycobacterium tuberculosis is mediated by an ancestral prokaryotic proofreader.

Authors:  Jeremy M Rock; Ulla F Lang; Michael R Chase; Christopher B Ford; Elias R Gerrick; Richa Gawande; Mireia Coscolla; Sebastien Gagneux; Sarah M Fortune; Meindert H Lamers
Journal:  Nat Genet       Date:  2015-04-20       Impact factor: 38.330

5.  Cordycepin kills Mycobacterium tuberculosis through hijacking the bacterial adenosine kinase.

Authors:  Feng Huang; Weihui Li; Hui Xu; Huafeng Qin; Zheng-Guo He
Journal:  PLoS One       Date:  2019-06-14       Impact factor: 3.240

6.  Structure-Guided Drug Design of 6-Substituted Adenosine Analogues as Potent Inhibitors of Mycobacterium tuberculosis Adenosine Kinase.

Authors:  Roberto A Crespo; Qun Dang; Nian E Zhou; Liam M Guthrie; Thomas C Snavely; Wen Dong; Kimberly A Loesch; Takao Suzuki; Lanying You; Wei Wang; Theresa O'Malley; Tanya Parish; David B Olsen; James C Sacchettini
Journal:  J Med Chem       Date:  2019-04-19       Impact factor: 7.446

7.  A bicyclic S-adenosylmethionine regeneration system applicable with different nucleosides or nucleotides as cofactor building blocks.

Authors:  Désirée Popadić; Dipali Mhaindarkar; Mike H N Dang Thai; Helen C Hailes; Silja Mordhorst; Jennifer N Andexer
Journal:  RSC Chem Biol       Date:  2021-03-22
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.